Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

TL;DR

  • Daraxonrasib, a KRAS inhibitor pill, is showing remarkable results in a trial for advanced pancreatic cancer.
  • Tumours stopped growing in 90% of patients, and became undetectable in about 8% of participants.
  • Survival rates at one year were significantly higher (76.6%) compared to chemotherapy alone (40-45%).
  • The drug works by targeting specific mutations that drive tumour growth.
  • There is potential for daraxonrasib to be effective against other cancers with similar mutations.
  • While promising, further research is needed to determine its long-term efficacy and potential as a cure.